Office-use compounding in Idaho

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The Board of Pharmacy rule chapter was voided in its entirety on 1 July 2025High confidence

This is the most important fact about Idaho and the least visible one. House Bill 200 moved the Board’s rules into statute, and section 50 of that bill carried a sunset clause that made the whole of IDAPA 24.36.01 null, void and of no force and effect from 1 July 2025. A page citing any rule number in that chapter is citing a chapter the legislature voided, and the revocation is quotable from the Rules Coordinator’s own bulletin.

Where Idaho compounding law lives nowHigh confidence

In statute, at Idaho Code §§ 54-1765 to 54-1767 — general compounding provisions, sterile preparations, and hazardous drugs. Each carries the stamp "added 2025, ch. 93" in its own history line, so their newness is checkable on the face of the section.

The office-use text is an exception to a criminal prohibition, not a grantHigh confidence

This is worth reading precisely. Section 54-1732(3) is a list of unlawful acts. Limb (d) makes wholesale distribution by a pharmacy unlawful, and then excepts several transactions from that, one of which uses the term "office use" outright. So the statute tells you the transaction is not the offence it just created. It does not, in its own words, authorise compounding for that purpose.

And the definition of compounding runs the other wayHigh confidence

Compounding is defined as creating a medication tailored to the needs of an individual patient. Non-patient-specific office stock does not obviously fit that definition, and anything the chapter does not permit is deemed manufacturing — which is a licensure question rather than a practice one. Neither "Idaho permits office use" nor "Idaho prohibits office use" survives contact with both texts, which is why this page states the split instead.

"Minimal quantities" is undefinedHigh confidence

The exception is measured by that phrase and nothing else. No number, no formula and no board interpretation appears in the sources we read, and the rule layer that might have supplied one was revoked. It cannot be used as a compliance ceiling because there is nothing to measure against.

Anticipatory compounding is allowed and is tethered to prescribing historyHigh confidence

Limited quantities may be compounded or sterile prepackaged before a valid prescription drug order arrives, based on a history of receiving valid prescription drug orders for that product. That is named-patient stock built on a pattern, not office stock — the same shape as the federal anticipatory provision.

Sterile preparations are governed separately, and the reclassification reaches bothHigh confidence

Section 54-1766 deals with sterility by dosage form. The manufacturing reclassification in § 54-1765(1) is not limited by sterility, so it reaches sterile and non-sterile alike. There is no non-sterile concession to fall back on.

Label requirements for office stock are not establishedMedium confidence

The statutory sections carry quality and process duties rather than a label format for non-patient-specific stock. Whatever legend requirement previously existed lived in the revoked rule chapter, so there is currently nothing to report and nothing to comply with.

Idaho at a glance

Receiving 503B office stock in Idaho

Idaho names the credential using the literal industry term, which makes its law searchable, and it puts a federal precondition inside the state definition. The board itself now sits inside a larger licensing department, which is where a reader looking for it will need to go.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Idaho asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

Both halves at once, and the definition says so: registration with the FDA under 21 U.S.C. 353b, and registration or endorsement by the Idaho board. Federal registration alone is a precondition to the state credential rather than a substitute for it. The non-resident outsourcing facility fee is $500 initially and $250 on renewal.

Does your practice need a permit?Medium confidence

For controlled substances, yes: Idaho issues a named practitioner controlled substance registration, at a fee of $60. For non-controlled office stock the sources we read do not impose a separate practice credential, and that absence is reported as an absence rather than as a clearance.

Administer vs dispenseHigh confidence

The statutory exception itself distinguishes them: it covers sales to practitioners for office use and, as a separate limb, sales to dispensing drug outlets for a specific patient need. Supply to a practitioner and supply for onward dispensing are written as different transactions with different conditions.

Scheduled (controlled) stockHigh confidence

Idaho requires its own practitioner controlled substance registration, which is a certificate held by a named person rather than by the practice entity. Registration runs through the Board of Pharmacy, which now sits within the state’s Division of Occupational and Professional Licenses.The board’s long-standing standalone web address no longer resolves at all, so a reader working from an older citation will find nothing rather than a redirect.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• This page deliberately publishes Idaho’s split rather than a verdict, because Idaho’s own law does not currently resolve it. Two in-force texts point in opposite directions and the rule chapter that sat between them was revoked. Anyone who needs a working answer should put the question to the Board rather than rely on either half.
• If the Board promulgates a new rule chapter, that chapter could resolve the split in either direction, and this page would need re-reading from scratch. No proposed replacement text was available when it was written.
• One trap worth knowing if you check the bulletins yourself: the administrative bulletin archive served identical bytes at two different years’ addresses, so a correct-looking address can return the wrong year silently. Only the July 2025 bulletin cited here was confirmed to be the document it claims to be.
• The practical meaning of "minimal quantities" is beyond the scope of this page. No number, formula or board interpretation exists in the material we read.
• We searched no case law, attorney-general opinions or declaratory rulings for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.